Acquired pure megakaryocytic aplasia is a rare hematological disorder characterized by thrombocytopenia with absent or markedly reduced megakaryocytes in the bone marrow. We report a case of a 25-year-old male diagnosed as acquired pure megakaryocytic aplasia. Treatment with prednisone and intravenous immunoglobulin failed, but he was successfully treated with cyclosporine, with complete remission after 90 days and normal platelet count maintained thereafter. (Turk J Hematol 2010; 27: 289-93) Key words: Acquired amegakaryocytic thrombocytopenia, steroids, cyclosporine 
Introduction
Megakaryocytic aplasia, especially acquired pure megakaryocytic aplasia (APMA), is a rare hematologic disorder. APMA is characterized by severe thrombocytopenia resulting from marked decrease or absence of megakaryocytes in the marrow in the presence of otherwise normal erythropoiesis and granulopoiesis. APMA can be either idiopathic or caused by a variety of conditions, such as acquired clonal cytogenetic abnormalities, drug sensitivity, toxin exposure, infectious diseases such as viral infection [1, 2] , immune diseases such as lupus erythematosus [3] , systemic sclerosis [4] , eosinophilic fasciitis [5] , and malignancy [6, 7] . Patients with acquired amegakaryocytic thrombocytopenia may have additional hematological abnormalities such as macrocytosis or dyserythropoiesis, abnormalities which may indicate potential future progression to aplastic anemia or myelodysplasia [8] [9] [10] .
Case Report
A 25-year-old male from Nepal presented in August 2008 with a one-week history of headache, gum bleeding and epistaxis. There was no history of trauma, arthralgia, weight loss, drug intake, alcohol consumption, or fever and no family history of bleeding diathesis. He was not known to have any chronic disease. Physical examination showed multiple ecchymoses and petechiae all over the body with bilateral retinal hemorrhage. He had no hepatosplenomegaly or lymphadenopathy.
Complete blood count showed white blood cells (WBC) 9.7x10 9 /L with normal differential, hemoglobin (Hb) 9.1 g/dl, mean corpuscular volume (MCV) 102 fl, reticulocytes 7.2% (total 210x10 9 /L), and platelet (PLT) count 5x10 9 /L. Peripheral blood smears revealed normochromic normocytic red cells with polychromasia and markedly decreased PLT. Direct and indirect Coombs tests were negative; prothrombin time, partial thromboplastin time, liver and renal function tests, serum iron, transferrin saturation, serum B12, red cells, and serum folate were all normal. Autoimmune screen including anticardiolipin, antinuclear antibodies, rheumatoid factor, and C3 and C4 were negative. Serological markers for infections like hepatitis virus (A, B & C) and antibodies against human immunodeficiency virus (HIV), rubella, cytomegalovirus, varicella, herpes simplex virus types 1& 2, Epstein-Barr virus (EBV) and Toxoplasma gondii were all negative; serological test for parvovirus B19 was not done.
The magnetic resonance imaging (MRI) of the brain showed multiple subcentrimetric foci of hemorrhagic lesions in the left and right parietal regions and in the frontal region. Computed tomography scan of the chest, abdomen and pelvis was normal.
Bone marrow aspiration revealed complete absence of megakaryocytes in an otherwise normocellular marrow with active erythro-and granulopoiesis, with no dysplastic features or abnormal cell infiltrates. Iron stores were depleted. The histology of the biopsy and immunohistochemistry using CD61 antibody (GPIIIa) confirmed the isolated megakaryocytic aplasia (Figure 1 ). Cytogenetic analysis of the bone marrow showed a normal male In view of the widespread hemorrhage and MRI findings, the patient was treated initially with PLT transfusion and methylprednisolone 5 mg/kg/day intravenous (IV) for 3 days followed by oral dose of prednisone 1 mg/kg/day that was continued for 2 weeks and then tapered over 4 weeks until discontinuation. On Day 5 of steroid, no response was obtained, so empirical intravenous immunoglobulin (IVIG) 1 g/kg/day for 2 days was added, but again no significant response was achieved. Oral cyclosporine 5 mg/kg/day was started on Day 12 of treatment, and 2 weeks later the PLT count began to rise and transfusions were no longer required.
The patient was discharged with a PLT count of 60x10 9 /L and was followed as an outpatient. Three months later, complete blood count normalized, PLT count was 148x10 9 /L with Hb of 14 g/dl, and the bone marrow follow-up was cellular with a good number of megakaryocytes and well-represented erythropoiesis and granulopoiesis (Figure 2 ). The patient is currently under follow-up with maintenance of a normal PLT count (Figure 3 ) on the same dose of cyclosporine, with satisfactory therapeutic levels and normal renal function. The plan is to continue cyclosporine for up to one year with gradual tapering of the dose before stopping. Waiver consent is available at Hamad Medical Corporation Research office. 
Omri et al. Acquired amegakaryocytic thrombocytopenia treated with cyclosporine Turk J Hematol 2010; 27: 289-93

Discussion
Isolated thrombocytopenia and megakaryocytic aplasia, inconsistently described as APMA or acquired amegakaryocytic thrombocytopenia purpura (AATP), is a rare disease in the field of hematology. The exact prevalence is unknown and the available literature comprises case reports and small case series. It is possible that the incidence rate is higher than what is reported and that many of the cases are underdiagnosed or misdiagnosed as immune thrombocytopenia [10] . The clinical course of this rare disease seems to be variable. In some patients, it progresses rapidly to aplastic anemia [8] or myelodysplasia [9] . The usual clinical presentation of APMA is with bruising and bleeding with the absence of splenomegaly.
The exact pathogenesis behind this disease is still uncertain; several studies suggest an immunemediated process. Benedetti et al. [11] showed cell-mediated immunosuppression of megakaryocytes by demonstrating a marked increase in T-activated suppressor cells (CD8+/DR+) in association with AATP. A role for humoral immunity was also proposed in the pathogenesis of AATP when Katai et al. [12] showed significant suppression of megakaryocyte colony formation of normal marrow cells with the addition of AATP patient serum to marrow cultures. Antibodies against thrombopoietin have been described to cause this disorder [13] , as have antibodies against the TPO receptor, the c-mpl [3, 14] . Chromium-tagged survival studies in patients with APMA have shown normal results, ruling out PLT destruction or sequestration [15] .
Due in part to the heterogeneous nature of the syndrome and the variety of the pathogenic mechanisms, no standard treatment has been established; however, several empirical therapies are used in patients with AATP and include the administration of corticosteroids , IVIG, cyclophosphamide, vincristine, cyclosporine, anti-thymocyte globulin (ATG), splenectomy [15] [16] [17] [18] , allogenic bone marrow transplantation [19] , and recently, mycophenolate mofetil [20] .
The administration of corticosteroids, IVIG, cyclophosphamide, vincristine, androgens, and mycophenolate mofetil are transiently effective in occasional patients with AATP [1, 15, 16, 20] ; however, the administration of cyclosporine alone or in combination with ATG was shown to be very effective in the treatment of AATP [10, 15, 17, 18] .
Our patient represents a typical case of APMA with severe thrombocytopenia and absent marrow megakaryocytes. Predictors that indicate the disease progression such as clonal cytogenetic abnormalities, macrocytosis or dyserythropoiesis were not present; the anemia was explained by the significant mucocutaneous bleeding or autoimmune mechanism. No obvious cause of the APMA could be found in this patient. There was no history of exposure to chemicals or drugs, and clinical examination and investigations excluded collagen diseases, infections, malignancies, and congenital anomalies like absent radius. Unfortunately, tests for TPO and c-MpI antibodies are not available in our center.
The response to immunosuppressive treatments, especially the cyclosporine, would suggest an immune-mediated pathogenetic mechanism. Normalization of the PLT count was achieved 90 days after the start of treatment. As of the preparation of this report, the patient is well, with a PLT count of 198x10 9 /L and Hb of 14 g/dl, maintained on 5 mg/kg/day cyclosporine (for 7 months from the initiation of treatment), with continuing monitoring to ensure response and to detect any progression to aplastic anemia or myelodysplastic syndrome.
In conclusion, this case report supports the effectiveness of cyclosporine at the prescribed dose of 5 mg/kg/day in the management of APMA.
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